BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $401,009 | -0.2% | 15,207 | -34.9% | 0.00% | 0.0% |
| Q2 2023 | $401,775 | +18.4% | 23,359 | +14.1% | 0.00% | 0.0% |
| Q1 2023 | $339,442 | +103.4% | 20,473 | -6.5% | 0.00% | +100.0% |
| Q4 2022 | $166,878 | -31.3% | 21,900 | -10.5% | 0.00% | 0.0% |
| Q3 2022 | $243,000 | +12.0% | 24,459 | +2.3% | 0.00% | 0.0% |
| Q2 2022 | $217,000 | -35.0% | 23,914 | -27.4% | 0.00% | 0.0% |
| Q1 2022 | $334,000 | +61.4% | 32,930 | +164.9% | 0.00% | 0.0% |
| Q4 2021 | $207,000 | -64.9% | 12,430 | -1.1% | 0.00% | -66.7% |
| Q3 2021 | $589,000 | -23.2% | 12,565 | -0.1% | 0.00% | 0.0% |
| Q2 2021 | $767,000 | -6.2% | 12,575 | -5.3% | 0.00% | -25.0% |
| Q1 2021 | $818,000 | -11.9% | 13,275 | +1.7% | 0.00% | 0.0% |
| Q4 2020 | $929,000 | +94.4% | 13,058 | +2.6% | 0.00% | +100.0% |
| Q3 2020 | $478,000 | +61.5% | 12,728 | +40.2% | 0.00% | +100.0% |
| Q2 2020 | $296,000 | – | 9,078 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |